Bis-pyrazole as receptor interacting protein 1 kinase inhibitor: Synthesis, preliminary biological evaluation against pancreatic cancer cell line and its docking studies

The pyrazole heterocycle displayed versatile pharmacological activity ranging from anti-inflammatory to antiviral. Herein, we report the synthesis of bis-pyrazole as receptor- interacting protein 1 kinase inhibitor and evaluated for antiproliferative activity against pancreatic cancer line, PANC-1. Among twelve compounds, three candidates displayed the cytotoxicity IC50 value in single digit micromolar concentration. From the preliminary evaluation, the compound 31 emerged as a potential inhibitor with an IC50 = 4.1 µM. The lead compound showed similar inhibitor IC50 value in comparison to the positive control, doxorubicin. The docking studies confirm that these analogs may require further investigation to improve the potency.